



## 47th Joint Coordination Meeting of Arab and CCNE Codex Contact Points

Preparation for the 28th Session of the Codex Committee on  
Residues of Veterinary Drugs in Foods (CCRVDF28)

*Presented by [Oman, Jordan]*

*[March] [17], 2026*

## Agenda Item 10 – Documents

### Relevant documents include:

- REP24/RVDF27 – Appendix VII
- CX/RVDF 26/28/12
- CX/RVDF 26/28/10

### These documents compile:

proposals from Codex Members

comments submitted through Circular Letters

candidate veterinary drugs for JECFA evaluation.

## Status in Codex Process

- Ongoing work within CCRVDF.
- Members submitted proposals for veterinary drugs requiring evaluation or re-evaluation.
- The Priority List Working Group will review submissions.
- The Working Group will provide a report for consideration by CCRVDF28.

### Outcome may lead to:

- JECFA scientific evaluation
- Establishment or revision of Codex MRLs.

# Background

The Priority List of Veterinary Drugs is an essential component of the Codex risk analysis framework.

It identifies veterinary drugs requiring scientific evaluation to establish:

- Health-Based Guidance Values (HBGVs)
- Acceptable Daily Intake (ADI)
- Maximum Residue Limits (MRLs)

Scientific advice from JECFA supports Codex decisions on MRLs.

## Purpose of the Agenda Item

The Committee will review and update the Priority List of Veterinary Drugs to ensure that:

- substances relevant to public health protection
- veterinary drugs widely used in food-producing animals
- substances affecting international trade

are scientifically evaluated in a timely manner.

# Key Criteria for Prioritization

**The Committee may consider several factors:**

- **Extent of veterinary drug use**
- **Potential residues in food**
- **Public health relevance**
- **Antimicrobial resistance (AMR)**
- **Trade implications**
- **Availability of scientific data**

**These factors guide the prioritization of substances for JECFA evaluation.**

# Key Technical Considerations

Important elements include:

## Veterinary drug use

Widely used drugs may lead to residues in food products.

## Human dietary exposure

Consumers may be exposed through meat, milk, eggs, fish, and honey.

## Public health impact

Toxicological effects such as carcinogenicity or reproductive toxicity.

## Antimicrobial resistance (AMR)

Particularly for antimicrobials classified as critically important.

## Availability of Scientific Data

**JECFA evaluation depends on the availability of:**

- toxicological studies
- metabolism data
- residue depletion studies
- validated analytical methods

**Without adequate data, a reliable risk assessment cannot be conducted.**

# Examples of Veterinary Drugs for Future Evaluation

Examples of substances potentially relevant for prioritization include:

- Enrofloxacin
- Florfenicol
- Tilmicosin
- Toltrazuril
- Diclazuril
- Ivermectin
- Colistin
- Ketoprofen

Prioritization depends on:

- veterinary use
- public health relevance
- availability of scientific data.

## Positions of Codex Members

Country	Periority List & Actions
Egypt	<ul style="list-style-type: none"> <li>- Proposed inclusion of Nitrofurans for evaluation, particularly residues detected in casings derived from animal offal</li> <li>- Proposed consideration of Sulfonamides (e.g., sulfadimidine) in honey and bee products</li> <li>- Highlighted potential public health concerns and the availability of LC-MS/MS analytical detection methods</li> </ul>
United States	<p>. Proposed additional substances for evaluation:            * Doramectin – Ketoprofen - Pradofloxacin</p>
United Arab Emirates	<ul style="list-style-type: none"> <li>- Expressed support for the current priority list.</li> <li>- Highlighted the regional importance of camelids</li> <li>- Supported the use of extrapolation approaches where scientifically justified</li> </ul>
Malaysia	<ul style="list-style-type: none"> <li>- Expressed support for the ongoing work of CCRVDF and the current prioritization process</li> </ul>
New Zealand	<ul style="list-style-type: none"> <li>- Highlighted the importance of robust scientific data when applying extrapolation approaches</li> </ul>

# Positions of Codex Members

Country	Priority List & Actions
Jordan & Oman	<ul style="list-style-type: none"><li>- Supports the science-based prioritization process used by CCRVDF.</li><li>- Takes note of Member proposals including nitrofurans and sulfonamides.</li><li>- Supports evaluation of veterinary drugs where adequate scientific data are available.</li><li>- Recognizes the importance of harmonized international standards to facilitate trade and protect public health.</li><li>- Notes the regional relevance of camelids and supports extrapolation approaches when supported by scientific evidence.</li></ul>

# Public Health Considerations

Veterinary Drug	Public Health Considerations
<u>Nitrofurans</u>	<ul style="list-style-type: none"><li>- Associated with carcinogenic and genotoxic metabolites.</li><li>- Use prohibited in many jurisdictions</li><li>- Residues may occur due to illegal use</li></ul>
<u>Sulfonamides</u>	<ul style="list-style-type: none"><li>- Possible allergic reactions</li><li>- Potential contribution to antimicrobial resistance</li><li>- Effective residue monitoring programmes remain essential.</li></ul>

# Trade Considerations

The absence of Codex MRLs may lead to:

- regulatory divergence among countries
- trade disruptions
- rejection of food consignments
- increased compliance costs

Updating the Priority List contributes to international harmonization of food safety standards.

# Key Points for Delegates

## Delegates may wish to consider:

- The importance of the **Priority List** in guiding JECFA work.
- **Public health** relevance and **AMR** considerations.
- The impact of missing **Codex MRLs** on international trade.
- The need for sufficient scientific data to support evaluations.
- The value of collaboration among **Codex Members**.

# Recommendations

## Option 1

Support updating the Priority List and encourage submission of scientific data to support JECFA evaluations.

## Option 2

Support the update while encouraging further discussion on prioritization criteria including:

- public health relevance
- AMR considerations
- patterns of veterinary drug use
- availability of scientific data.

